The Journal of Dental Panacea

Online ISSN: 2348-8727

CODEN : JDP

The Journal of Dental Panacea (JDP) open access, peer-reviewed quarterly journal, Publish quarterly as Open Access (OA).  Vision of this journal  for better dissemination of knowledge, Journal will be publishing the article ‘Ahead of Print’ immediately on acceptance. In addition, the journal would allow free access (Open Access) to its contents, which is likely to attract more readers and citations to articles published in JDP. Manuscripts must be prepared in accordance with “Uniform requirements” of the The Journal of Dental Panacea as more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 297

PDF Downloaded: 152


Get Permission Sreenivasulu, Vishwanathan, Prasad, Sowjanya, Anitha R, and Deepthi P: Effects of non-surgical periodontal therapy (NSPT) in prediabetes patients with periodontitis - A randomised control trial


Introduction

Diabetes mellitus is a highly prevalent metabolic disorder, constituting a serious public health burden. A predicted 300 million people are going to suffer from diabetes by 2025.1 India has one of the highest incidence rates for diabetes with more than 62 million suffering from diabetes and a projected increase to 80 million by 2030. 2

Pre diabetes means your blood glucose levels are higher than normal but not high enough to be diagnosed as diabetes. Pre diabetes usually occurs in people who already have some insulin resistance or whose beta cells in the pancreas aren’t making enough insulin to keep blood glucose in the normal range. Without enough insulin, extra glucose stays in bloodstream rather than entering your cells and over time, patient can develop type 2 diabetes. 2

Hyperglycemia is known to favor pro-inflammatory priming of periodontal tissues thus contributing to the earlier onset of gingivitis, the initial and reversible stage of periodontitis, in patients with diabetes. 3 Periodontitis elevates the systemic inflammation leading to a state of insulin resistance precipitating into hyperglycemia and advanced glycation end product accumulation. 4

Persistent hyperglycemic state and advanced glycation end product besides causing the macrovascular and microvascular complications of diabetes also result in the impaired gingival fibroblast synthesis, defective phagocytic activity of mononuclear and polymorphonuclear cells. 5 This may result in the loss of periodontal fibers and supporting alveolar bone.5 These findings led to consider periodontitis as the sixth complication of diabetes mellitus. 6 The association between periodontal disease and diabetes has been explored in several studies over the years, and it is generally accepted that periodontal disease is more prevalent and more severe in persons with diabetes than in non diabetic persons.

The impact of Diabetes mellitus on periodontal health has been addressed in numerous cross-sectional and longitudinal studies and Diabetes mellitus is currently considered an established risk factor for Periodontal disease. Although there is significant heterogeneity among these studies in design and definition of periodontal disease, increasing evidence suggests that poorly controlled Diabetes mellitus correlates with higher prevalence, severity, and progression rate of Periodontal disease when compared to controlled Diabetes mellitus or health. 7, 8, 9, 10, 11

CRP is an acute-phase protein mainly produced by the liver in response to infection or tissue damage.12 Connecting peptide (C-peptide), produced in equal amounts to insulin, is known to be a useful marker of beta-cell function and can be used to assess endogenous insulin secretion. 13 Obesity (body-mass index [BMI]≥30 kg/m2) is the strongest risk factor for Type 2 Diabetes mellitus and is associated with metabolic abnormalities resulting in insulin resistance.6 Insulin and C-peptide responses to oral glucose load are found significantly higher in smokers than non-smokers. In addition to increased insulin resistance, smoking also showed dyslipidaemia and make subjects prone to atherosclerosis. Smokers had higher fasting triglycerides and lower high density lipoprotein cholesterol levels, and an increased proportion of small dense low density lipoprotein particles. Fibrinogen levels and plasminogen activator inhibitor 1 activity were also seen elevated in smokers. 6

In the present study, the association of periodontitis and pre-diabetes was evaluated clinically and microbiologically. Clinically, the probing depth, CAL, Bleeding on Probing were evaluated at baseline and postoperatively (NSPT-Non Surgical Periodontal Therapy) at 6 weeks and 12 weeks of intervals. The microbial load in pre-diabetes patients was assessed using samples collected from the periodontal pockets ≤5mm by gram staining. The effect of periodontal therapy in pre-diabetes conditions was assessed using Homeostasis Model assessments of IR and β-cell function (HOMA-IR and HOMA-β). BMR, FBS, post prandial blood sugar, Fasting insulin.

Materials and Methods

The study was designed as a randomized controlled clinical trial to clinically study the relationship between pre-diabetes mellitus and periodontitis by evaluating HOMA-IR & HOMA-β .Subjects for the study were selected from Out-Patient section of the Department of Periodontology, MNR Dental College & Hospital, Sangareddy District, Telangana and were followed for 6 weeks and 12 weeks period after the post NSPT as baseline. The current randomised clinical trial was done on 100 participants. Systemically healthy (Non-diabetic) male and female patients of age group 20-50 years with complaints of periodontal disease having probing pocket depth of ≤5mm and CAL ≤4mm were included in the study. Medically compromised patients, subjects who underwent radiotherapy or chemotherapy in the past 12 months, patients having uncontrolled periodontal disease, having ≤15 teeth and Pregnant and lactating women were excluded.

Sample size calculation

Sample size calculation was performed using G power 3.1 software. The calculations were based on the probability of Pre diabetes between Periodontitis and Non-Periodontitis groups with an alpha level of 0.05, a desired power of 80%. The estimated sample size was 84 subjects. Considering 20% loss of follow up before completion of the trial, a total of 100 (50 in each group) subjects were included in the study. The study was designed as a single blind, randomized controlled clinical trial where in the relationship between pre-diabetes mellitus and periodontitis was studied by evaluating HOMA-IR & HOMA-β with following groups: Test group: patients with chronic periodontitis with prediabetes and Control group: patients with chronic periodontitis without prediabetes This blind was not broken until this clinical trial was completely finished at the end of 12 weeks.

PPD and CAL, Bleeding on probing were recorded at the baseline, at the end of 6 weeks and 12 weeks using a UNC-15 color-coded periodontal probe. An alginate impression was taken and custom acrylic stent limited to the occlusal 2/3rds of the clinical crown were used as fixed reference position (i.e. junction of vertical groove and lower border of the stent). A groove was prepared in the stent to standardize the probing angulation throughout the study period.

Patient protocol

Each patient was prepared for the study with NSPT (Non Surgical periodontal Therapy) which included scaling and root planing (SRP), occlusal adjustment and oral hygiene instructions. On completion of the initial examination and thorough phase-I therapy, the patients were reassessed at 6 weeks and 12 weeks.

Blood samples were collected from the patient and the parameters - Fasting blood glucose, post prandial blood sugar, Fasting insulin are measured at baseline, 6 weeks and 12 weeks.

HOMA-IR and HOMA-β cell function

The homeostasis model assessment index, HOMA-IR and HOMA-β were used for measurement of insulin resistance and beta cell function (insulin secretion capacity), respectively. Both indexes were calculated using the following formula:

HOMA-IR = Fasting plasma glucose (mg/dL) × Fasting insu lin (mIU/L)/ 05

HOMA-β = 360 × Fasting insulin (mIU/L)/ [Fasting plasma glucose (mg/dL)-63].

Microbiological assessment

Plaque samples are collected from mesiobuccal pocket (PPD 5-7mm) and gram staining was done.

Statistical analyses

The data collected were entered into Microsoft excel 2018. Statistical analysis was done using IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp. Descriptive analyses were done. Student’s t-test, repeated measures of ANOVA were used for determination of the significance of HOMA-IR, HOMA-β mean differences between and within the groups. Multivariate logistic regression analysis was performed for calculation of odds ratios (OR) for the prevalence of both prediabetes and IFG by periodontitis category after adjustment of all possible covariates.

Results

A total of 100 sample, 50 each male and female are studied. Among them 26 were below 30yrs age. Most of them are having brushing habit of once a day,1/5 were smokers,1/4 were alcoholic. Around 50% were had physical activity. 80% were of more than 25 BMI.

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/01dd50f5-f95d-4d56-93b8-0824f2562797image1.png

This duration of study was 12 weeks. PPD and CAL, Bleeding on probing were recorded at the baseline to confirm chronic periodontitis, NSPT done to the all the patients after recording BMR, blood parameters like FBS, post prandial blood sugar, Fasting insulin. These are recorded at 6 weeks and 12 weeks post NSPT and data are studied to correlate with HOMA MODEL.

The homeostasis model assessment index, HOMA-IR and HOMA-β were used for measurement of insulin resistance and beta cell function (insulin secretion capacity), respectively and the results are as follows.

Table 1 On intergroup comparison of Microbial load between Control Group and Test group, a highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. However, control group showed no statistically significant difference (p<0.14) from baseline to 6 weeks and 12 weeks.

Table 1

Timeline

Mean

Standard Deviation

F Stat

P value

Control Group

Microbial Load Base Line

74

5.65

11.6

0.14

After 6 weeks

71

4.96

After 12 weeks

68

3.58

Test group

Microbial Load Base Line

78

6.23

84.2

0.0001***

After 6 weeks

71

5.25

After 12 weeks

66

4.22

Table 2 On intergroup comparison of BMI between Control Group and Test group a highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. However, control group showed no statistically significant difference (p<0.14) from baseline to 6 weeks and 12 weeks

Table 2

Timeline

Mean

Standard Deviation

F Stat

P value

Control Group

BMI base line

28.11

2.45

11.6

0.14

After 6 weeks

28.06

2.11

After 12 weeks

27.24

1.96

Test group

BMI base line

28.32

2.32

84.2

0.0001***

After 6 weeks

27.8

2.01

After 12 weeks

27.5

1.99

Table 3 On comparison of Periodontal probing depth between Control Group and Test group a highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. Similarly, control group too showed a statistically significant difference (p<0.002*) from baseline to 6 weeks and 12 weeks.

Table 3

Timeline

Mean

Standard Deviation

F stat

P Value

Control group

Periodontal probing depth base line

5.52

0.51

11.5

0.002*

After 6 weeks

5.25

0.33

After 12 weeks

5.02

0.15

Test group

Periodontal probing depth base line

5.55

0.28

73.9

0.0001***

After 6 weeks

5.13

0.6

After 12 weeks

5.01

0.2

Table 4 On comparison of Clinical Attachment Loss between Control Group and Test group a highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. Similarly, control group too showed a highly statistically significant difference (p<0.0005***) from baseline to 6 weeks and 12 weeks.

Table 4

Time line

Mean

Standard

Deviation

F stat

P Value

Control Group

CAL Baseline

2.42

0.09

17.56

0.0005***

After 6 weeks

2.27

0.19

After 12 weeks

2.16

0.24

Test Group

CAL Baseline

2.66

0.63

66.55

0.0001***

After 6 weeks

2.33

0.28

After 12 weeks

2.16

0.25

Table 5 On comparison of Gingival bleeding Index between Control Group and Test group a highly statistically significant difference (p<0.0001) was noted between both the groups from baseline to 6 weeks and 12 weeks

Table 5

Timeline

Mean

Standard Deviation

F Stat

P value

Control Group

GBI Score Base Line

50

15.65

81.7

0.0001***

After 6 weeks

41.04

13.65

After 12 weeks

33.92

13.69

Test group

GBI score base line

54.18

10.07

657.6

0.0001***

After 6 weeks

44.42

10.11

After 12 weeks

36.72

11.46

Table 6 On intergroup comparison of Fasting blood sugar values between Control Group and Test group no significant difference was noted in both the groups from baseline to 6 weeks and 12 weeks.

Table 6

Timeline

Mean

Standard Deviation

F Stat

P value

Control Group

FBS base line

112.9

7.88

1.26

0.41

After 6 weeks

111.8

7.12

After 12 weeks

111.2

6.87

Test group

FBS base line

113.2

8.61

3.21

0.29

After 6 weeks

112.1

8.09

After 12 weeks

110.4

7.87

Table 7 On intergroup comparison of Post prandial blood sugar between Control Group and Test group, a highly statistically significant difference (p<0.016**) was noted in the test group from baseline to 6 weeks and 12 weeks. However, control group did not show a statistically significant difference (p<0.12) from baseline to 6 weeks and 12 weeks.

Table 7

Timeline

Mean

Standard Deviation

F Stat

P value

Control Group

PPBS base line

125.9

6.92

3.1

0.12

After 6 weeks

125.4

6.12

After 12 weeks

124.9

5.32

Test group

PPBS base line

126.7

7.00

4.2

0.016**

After 6 weeks

125.7

6.07

After 12 weeks

124.2

5.21

Table 8 On intragroup comparison of HOMA-IR values a highly statistically significant difference (p<0.0001*) was noted from baseline to 6 weeks and 12 weeks.

Table 8

Timeline

Mean

Standard Deviation

F stat

P value

HOMA -IR base line

2.90

1.54

52.3

0.0001*

HOMA- IR 6 weeks

1.71

1.21

HOMA- IR 12 weeks

0.72

0.54

Table 9 On comparison of HOMA- IR between Control Group and Test group a highly statistically significant difference (p<0.0001) was noted between both the groups from baseline to 6 weeks and 12 weeks

Table 9

Timeline

Mean

Sd

F

P Value

Control group

HOMA -IR at baseline

0.68

0.2

80

0.0001***

HOMA -IR After 6 Weeks

0.68

0.2

HOMA -IR After 12 Weeks

0.64

0.19

Test Group

HOMA -IR at baseline

3.43

1.74

52.3

0.0001***

HOMA -IR After 6 Weeks

3.28

1.56

HOMA -IR After 12 Weeks

3.1

1.43

Table 10 On intragroup comparison of HOMA-β values a statistically significant difference (p<0.001**) was noted from baseline to 6 weeks and 12 weeks.

Table 10

Timeline

Mean

Standard Deviation

F stat

P value

HOMA -β Base Line

45.114

8.312

45.04

0.001**

HOMA-β 6 weeks

57.654

4.364

HOMA -β12 weeks

88.068

3.147

Table 11 On comparison of HOMA-β between Control Group and Test group a highly statistically significant difference (p<0.001) was noted between both the groups from baseline to 6 weeks and 12 weeks.

Table 11

Timeline

Mean

Sd

F

P value

Control group

HOMA- β at baseline

42.410

3.121

42.31

0.001**

HOMA- β After 6 Weeks

54.125

3.245

HOMA -β After 12 Weeks

86.147

4.165

Test Group

HOMA- β At Baseline

44.272

4.321

43.04

0.0001*

HOMA -β After 6 Weeks

58.198

5.177

HOMA β After 12 Weeks

88.724

6.144

Discussion

In the present study, the association of periodontitis and pre-diabetes was evaluated clinically and microbiologically at the baseline, and postoperatively at 6 weeks and 12 weeks of intervals. The microbial load in pre-diabetes patients was assessed using samples collected from the periodontal pockets ≤5mm by gram staining. The effect of periodontal therapy in pre-diabetes conditions was assessed using Homeostasis Model assessments of IR and β-cell function (HOMA-IR and HOMA-β), FBS, post prandial blood sugar and Fasting insulin.

In the present study, the clinical parameters PPD, clinical attachment level, Bleeding on probing were correlated with HOMA-IR, HOMA-β, BMR, FBS, post prandial blood sugar, Fasting insulin at regular intervals to learn about the association of periodontitis and pre-diabetes and also to know whether if the periodontal therapy (non-surgical) could aid in preventing the progression of pre-diabetic condition to diabetes. The nonsurgical periodontal treatment remains the gold standard for managing the periodontal patients. It can result in the reduction of inflammation, pocket depth reduction and clinical attachment gain. There is no certain magnitude of initial probing pocket depth where nonsurgical periodontal therapy is no longer effective. However, it needs to be emphasized that the root instrumentation is only indicated for sites with probing depth 4mm and above as instrumenting shallow sites will potentially develop the loss of attachment. Yet, no other therapeutic modality can be routinely utilized for the nonsurgical periodontal treatment than the scaling and root debridement or planing or instrumentation. The periodontal treatment is comprised of a bidirectional effort between the clinician and the patient to achieve the best therapeutic outcome. Therefore, the role of a high quality root debridement along with the implementation of a risk factor modification approach (oral hygiene habits, patient’s motivation and education, smoking cessation, diabetes control, healthy lifestyle changes) in the management of periodontitis is paramount. Obesity is also a key factor in the occurrence of metabolic syndrome and is strongly linked with insulin resistance (Eckel et al. 2005, Grundy 2005).14, 15 Based on an experimental, controlled, animal study, Amar et al.(2007)16 have suggested that obesity may disturb immune host defence to periodontal pathogens such as Porphyromonas gingivalis, and thus promote periodontitis. In human studies, a high BMI and a high waist– hip ratio have been related to periodontitis or deep pockets in various populations including young and older subjects, men and women (Saito et al. 2001, 2005).17, 18 A dose dependent relationship between the BMI and deep periodontal pockets has also been described in low-risk middle aged subjects such as non-diabetic, non-smoking people (Ylostalo et al. 2008).

In the present study on comparison of BMI between Control Group and Test group a highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. However, control group showed no statistically significant difference (p<0.14) from baseline to 6 weeks and 12 weeks. Therefore, we can infer that periodontal intervention is helpful for glucose control and insulin sensitivity improvement, which may be associated with decreased serum inflammatory cytokines and increased serum adiponectin levels.

A thorough review by Cobb (1996)19 has been often sited regarding the expected outcomes of nonsurgical periodontal treatment in probing depth reduction and clinical attachment gain at sites that initially were 4 to 6 mm in depth or greater than 7mm. He reported mean pocket depth reduction of 1.29 mm and 2.16 mm respectively and mean gain of clinical attachment of 0.55 and 1.29 mm respectively. So these results are similar to our present study. In the present study on comparison of Periodontal probing depth highly statistically significant difference (p<0.0001***) was noted in the test group from baseline to 6 weeks and 12 weeks. Similarly, control group too showed a statistically significant difference (p<0.002*) from baseline to 6 weeks and 12 weeks. On pairwise comparison a statistically significant difference (p<0.045*) was noted between 6 weeks and 12 weeks. There was a comparable difference in pocket probing depths from baseline to 12 weeks. Non-surgical treatment showed a decrease in probing pocket depth in these subjects. This could be attributed to the decrease in the disease activity caused by the treatment protocol.

In the present study on comparison of Clinical Attachment Loss between Control Group and Test group a highly statistically significant difference (p<0.0001***) was noted from baseline to 6 weeks and 12 weeks. This could be due to the reduction in bacterial load following non-surgical therapy (Haffajee et al 1997).20

Bleeding on probing (BOP) is an indicator of tissue inflammatory response to bacterial pathogens. The bleeding on probing (BOP) is a widely used clinical sign as indicator of the periodontal condition and disease progression. A study on this topic, published in 1990 by Lang and colleagues, demonstrates how the absence of BOP represents a reliable indicator of periodontal stability. We know, from the work by Löe et al. (1965), that the onset of gingivitis requires a presence of bacterial plaque for some length of time. Relative Risk analysis by L Checchi et al (2009) demonstrated that the incidence of BOP could be up to 6 times with calculus and up to 8 times with plaque. In the present study on comparison of Gingival bleeding Index between Control Group and Test group a highly statistically significant difference (p<0.0001) was noted between both the groups from baseline to 6 weeks and 12 weeks. This could be attributed to the decrease in the plaque and calculus caused by the treatment protocol and improvement in oral hygiene

In the present study comparison of Fasting blood sugar values between Control Group and Test group no significant difference was noted in both the groups from baseline to 6 weeks and 12 weeks. On intergroup comparison of Post prandial blood sugar between Control Group and Test group a highly statistically significant difference (p<0.016**) was noted in the test group from baseline to 6 weeks and 12 weeks. However, control group did not show a statistically significant difference (p<0.12) from baseline to 6 weeks and 12 weeks. This decrease in PPBS can be attributed to the decrease in inflammation and inflammatory markers (that causes insulin resistance) following non-surgical periodontal therapy.

Insulin resistance is central in the development of the metabolic disturbances encountered in the metabolic syndrome and is linked closely with glucose disorders (Matthews et al. 1985).21 Given that poor glycemic control is likely involved in the development of periodontitis (Tsai et al. 2002),22 insulin resistance may also play a central role. Many studies have clearly shown that inflammatory markers levels are higher in cases of periodontitis and increased levels of inflammatory markers causes insulin resistance (Chandrasekhar H et al. 2017). 23 Insulin sensitivity can be measured using different methods. In this study, we used the homeostasis model assessment (HOMA) method to yield an estimate of insulin sensitivity, because it has been shown to be a feasible method in large epidemiological studies for subjects of various ethnicities and varying degrees of glucose tolerance (Wallace et al. 2004).24 The HOMA method derives an estimate of insulin sensitivity from a mathematical model of fasting plasma glucose and insulin concentrations (Matthews et al. 1985).21 Periodontitis and insulin resistance (IR) show bidirectional relationship. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta-cell function. It was first described under the name HOMA by Matthews et al. in 1985.21

A recent study reported evidence of a close relationship of both HOMA-IR and HOMA-β in development of periodontal disease in subjects without diabetes (Timonen P et al, 2013). 25 Oelisoa M. Andriankaja et al (2018) 26 concluded that the baseline IR is associated with increased risk of gingival/periodontal inflammation at follow-up in the population of overweight/obese Hispanic adults. These findings have public health relevance, as prevention of IR through a healthy lifestyle may help reduce periodontal inflammation as well as diabetes. Nishioka S et al (2019) 27 concluded that among individuals diagnosed with borderline diabetes, those who had <37% of a lower BOP (%) showed potential improvements in BMI, fasting serum insulin, HOMA-IR, HOMA-β and Matsuda Index following non-surgical periodontal therapy. Similar to the above mention studies in this present study, also we can observe a highly statistically significant difference (p<0.0001*) was noted from baseline to 6 weeks and 12 weeks especially after nonsurgical periodontal therapy in test group for HOMA IR and HOMA-β values. This significant decrease in HOMA IR and HOMA-β values might be due to the decrease in circulation of inflammatory mediators (which are provoking for the development of insulin resistance) following nonsurgical periodontal therapy.

Conclusion

In the present study the clinical parameters PPD, clinical attachment level were evaluated and correlated with HOMA-IR, HOMA-β, BMR, FBS, post prandial blood sugar, fasting insulin at regular intervals to learn about the association of periodontitis and pre-diabetes and also to know whether if the periodontal therapy (non-surgical) could aid in preventing the progression of pre-diabetic condition to diabetes.

The conclusions from this study are

  1. There is significant association between prediabetes states and periodontitis.

  2. Early diagnosis of periodontitis and a proper treatment in prediabetic group can prevent the progression of prediabetic condition to diabetes and vise versa.

  3. Despite of extensive adjustment, remaining confounders may exist, such as other inflammatory biomarkers (interleukins for instance), poor tooth brushing habits (oral hygiene), or periodontal pathogens, habits (smoking, alcohol), gender etc.

  4. Smoking is a major risk factor for periodontitis but its relationships with metabolic syndrome and insulin resistance are more complex. So further research can be done to estimate the association between smoking, prediabetes, periodontitis, and their treatment outcomes.

  5. Further research can be done to assess association of prediabetic condition, periodontitis and the treatment outcomes in different genders and different age groups.

Source of Funding

None.

Conflict of Interest

There are no conflicts of interest.

References

1 

A Green NC Hirsch SK Prammingramming The changing world demography of type 2 diabetesDiabetes Metab Res Rev20031913710.1002/dmrr.340

2 

JE Shaw RA Sicree PZ Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract201087141410.1016/j.diabres.2009.10.007

3 

GE Salvi LM Franco TM Braun A Lee GS Rutger Persson NP Lang Proinflammatory biomarkers during experimental gingivitis in patients with type 1 diabetes mellitus: A proof&#8209;of&#8209;concept studyJ Clin Periodontol200937191610.1111/j.1600-051X.2009.01500.x

4 

SJ Janket JA Jones JH Meurman AE Baird TE Van Dyke Oral infection, hyperglycemia, and endothelial dysfunctionOral Surg Oral Med Oral Pathol Oral Radiol Endod20081052173910.1016/j.tripleo.2007.06.027

5 

M Kiran N Arpak E Unsal MF Erdoğan The effect of improved periodontal health on metabolic control in type 2 diabetes mellitusJ Clin Periodontol20053232667210.1111/j.1600-051X.2005.00658.x

6 

H Löe Periodontal disease. The sixth complication of diabetes mellitusDiabetes Care19931613293410.2337/diacare.16.1.329

7 

BL Mealey GL Ocampo Diabetes mellitus and periodontal diseasePeriodontol200744112753

8 

RT Demmer M Desvarieux B Holtfreter DR Jacobs H Wallaschofski M Nauck Periodontal Status and A1C Change: longitudinal results from the Study of Health in Pomerania (SHIP)Diabetes Care2010135103743

9 

WA Soskolne A Klinger The relationship between periodontal diseases and diabetes: An overviewAnn Periodontol200161918

10 

G Taylor W Borgnakke Periodontal disease: associations with diabetes, glycemic control and complicationsOral Dis2008143191203

11 

GW Taylor Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspectiveAnn Periodontol20016199112

12 

T Bansal A Pandey D Deepa AK Asthana C-Reactive Protein (CRP) and Its Association With Periodontal Disease: A Brief ReviewJ Clin Diagn Res201487ZE21510.7860/JCDR/2014/8355.4646

13 

AG Jones AT Hattersley The clinical utility of C-peptide measurement in the care of patients with diabetes20133078031710.1111/dme.12159

14 

RH Eckel SM Grundy PZ Zimmet The metabolic syndromeLancet2005365946814152810.1016/S0140-6736(05)66378-7

15 

SM Grundy A constellation of complications: the metabolic syndromeClin Cornerstone200572-3364510.1016/S1098-3597(05)80066-3

16 

S Amar Q Zhou Y Shaik-Dasthagirisaheb S Leeman Diet-induced obesity in mice causes changes in immune responses and bone loss manifested by bacterial challengeProc Natl Acad Sci U S A200710451204667110.1073/pnas.0710335105

17 

T Saito Y Shimazaki Y Kiyohara I Kato M Kubo M Iida Relationship between obesity, glucose tolerance, and periodontal disease in Japanese women: the Hisayama studyJ Period Res20054043465310.1111/j.1600-0765.2005.00813.x

18 

T Saito Y Shimazaki T Koga M Tsuzuki A Ohshima Relationship between upper body obesity and periodontitisJ Dent Res20018071631610.1177/00220345010800070701

19 

CM Cobb Non-surgical pocket therapy: mechanicalAnn Periodontol1996114439010.1902/annals.1996.1.1.443

20 

AD Haffajee MA Cugini S Dibart C Smith RL Kent Jr SS Socransky The effect of SRP on the clinical and microbiological parameters of periodontal diseasesJ Clin Periodontol19972453243410.1111/j.1600-051x.1997.tb00765.x

21 

DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia19852874129

22 

C Tsai C Hayes GW Taylor Glycemic control of type 2 diabetes and severe periodontal disease in the US adult populationCommunity Dent Oral Epidemiol20023031829210.1034/j.1600-0528.2002.300304.x

23 

H Chandrasekhar G Savitha MP Santhosh Kumar Evaluation of Association between Periodontitis and HyperlipidemiaJ Pharm Sci Res2017912242930

24 

TM Wallace JC Levy DR Matthews Use and abuse of HOMA modeling Diabetes Care2004276148795

25 

P Timonen T Saxlin M Knuuttila A L Suominen A Jula Role of insulin sensitivity and beta cell function in the development of periodontal disease in adults without diabetesJ Clin Periodontol20134010791086

26 

OM Andriankaja FJ Muñoz-Torres J Vivaldi-Oliver BG Leroux M Campos K Joshipura Insulin resistance predicts the risk of gingival/periodontal inflammationJ Periodontol201889554957

27 

S Nishioka K Maruyama T Tanigawa N Miyoshi E Eguchi W Nishida Effect of non-surgical periodontal therapy on insulin resistance and insulin sensitivity among individuals with borderline diabetes: A randomized controlled trialJ Dent201985182410.1016/j.jdent.2019.04.005



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.

Article type

Original Article


Article page

85-92


Authors Details

G Sreenivasulu, Krishnan Vishwanathan, K A Ravivarma Prasad, Kacharla Sowjanya, Anitha R, Deepthi P


Article History

Received : 12-05-2022

Accepted : 20-05-2022


Article Metrics


View Article As

 


Downlaod Files